engleski

Effects of gamma-amino-beta-hydroxy butyric acid (GABOB) on growth hormone (GH) release in patients with prolactinoma

The influence of orally administered GABOB on GH secretion has been studied in 39 normal volunteers and 30 patients with prolactinoma. In normal subjects the 5 g dose of GABOB increased serum GH levels from basal 0.409 +/- 0.029 ng/ml (mean +/- SEM) to a peak of 19.7 +/- 2.11 ng/ml at 90 min (p<0.001). In 17 patients with microprolactinoma the same dose of drug increased GH levels from basal 0.405 +/- 0.054 ng/ml to a peak of 13.2 +/- 2.56 ng/ml at 90 min (p<0.001), while in 13 patients with macroprolactinoma there was no change (basal 0.685 +/- 0.146 ng/ml vs. a peak of 0.782 +/- 0.119 ng/ml ; p>0.5). In conclusion, our results demonstrated a differential effect of GABOB on GH release in patients with prolactinoma, that may contribute to better delineation of these lesions.

GABOB; Growth hormone; Prolactinoma

nije evidentirano